Duration and onset of action of indacaterol, a novel 24-hour β2 -agonist, on isolated human bronchus
E. Naline, M. Molimard, R. Fairhurst, A. Trifilieff, C. Advenier (Paris, Bordeaux, France; Horsham, United Kingdom)
Source: Annual Congress 2005 - New perspectives in asthma treatment
Session: New perspectives in asthma treatment
Session type: Poster Discussion
Number: 1399
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Naline, M. Molimard, R. Fairhurst, A. Trifilieff, C. Advenier (Paris, Bordeaux, France; Horsham, United Kingdom). Duration and onset of action of indacaterol, a novel 24-hour β2 -agonist, on isolated human bronchus. Eur Respir J 2005; 26: Suppl. 49, 1399
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pharmacological characterization of indacaterol, a novel 24-hour β2 -agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Indacaterol, a novel 24-hour β2 -agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi Source: Eur Respir J 2007; 29: 575-581 Year: 2007
LAS100977, a novel β2 -agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2 -agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007
Cardiovascular safety of indacaterol, a novel 24-hour β2 -agonist, in patients with stable asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Single-dose indacaterol, a novel 24-hour β2 -agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Onset of action and effect of withdrawal of roflumilast in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Indacaterol, a novel once-daily β2 -agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
LAS100977 is a novel, potent β2 -agonist with rapid onset and sustained duration of action in vitro Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Abediterol, a novel long-acting inhaled beta2 -agonist, has a fast association rate and long residence time at human beta2 receptors Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Safety of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in moderate to severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014